FY2025 EPS Estimates for ADMA Biologics Raised by Analyst

ADMA Biologics, Inc. (NASDAQ:ADMA) – Research analysts at Cantor Fitzgerald upped their FY2025 earnings per share estimates for ADMA Biologics in a research note issued on Thursday, March 20th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will earn $0.73 per share for the year, up from their prior estimate of $0.70. Cantor Fitzgerald currently has a “Overweight” rating and a $25.00 target price on the stock. The consensus estimate for ADMA Biologics’ current full-year earnings is $0.51 per share.

ADMA Biologics Stock Down 4.7 %

NASDAQ:ADMA opened at $19.65 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The firm has a market cap of $4.65 billion, a P/E ratio of 70.18 and a beta of 0.60. ADMA Biologics has a fifty-two week low of $5.90 and a fifty-two week high of $23.64. The firm has a 50-day simple moving average of $16.74 and a two-hundred day simple moving average of $18.01.

Institutional Investors Weigh In On ADMA Biologics

Several institutional investors and hedge funds have recently made changes to their positions in ADMA. Larson Financial Group LLC purchased a new stake in ADMA Biologics during the 3rd quarter valued at $31,000. National Bank of Canada FI purchased a new stake in shares of ADMA Biologics during the third quarter valued at $35,000. GAMMA Investing LLC increased its holdings in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after buying an additional 967 shares in the last quarter. Mark Sheptoff Financial Planning LLC purchased a new position in ADMA Biologics in the 4th quarter worth about $35,000. Finally, Vision Financial Markets LLC purchased a new position in ADMA Biologics in the 4th quarter worth about $51,000. Institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.